Implementing Risk Assessment Tools for Personalized Management at Menopause

In: Journal of Mid-life Health · 2021 · vol. 12(3) , pp. 185–186 · doi:10.4103/jmh.jmh_167_21 · PMID:34759698 · W3207486999
editorial OA: diamond CC0
AI-generated deep summary by qwen3.7-flash, 2026-09-15 · read from full text

This editorial discusses the implementation of risk assessment tools to facilitate personalized management during the menopausal transition. It argues that objective models help organize complex clinical data, allowing practitioners to weigh individual benefit-risk profiles for conditions such as cardiovascular disease and breast cancer. The text emphasizes that these tools are essential for making informed treatment decisions tailored to a woman's unique biological and socioeconomic background. Relevance to endometriosis: The paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

DOAJ is a unique and extensive index of diverse open access journals from around the world, driven by a growing community, committed to ensuring quality content is freely available online for everyone.
Full text 4,275 characters · extracted from oa-doi-fallback · click to expand
Menopause medicine studies an adult woman passing through a transitional phase between reproductive and geriatric age groups. To practice menopause, I switched from the exciting and fast-paced role of an obstetrician and a surgeon to one of a family physician and a counselor. An immense satisfaction of bringing a smile and twinkle in the eye on a midlife woman's face replaces the thrill of delivering babies. Mastering menopausal medicine involves learning the basic knowledge and recent advances on not so familiar areas such as hypertension, diabetes, skeletomuscular health, and nutrition. Notably, constant interaction with colleagues of other disciplines and plenty of “time and patience” needs to be given to the individual woman. Webster defines diagnosis as “the art or act of identifying a disease from its signs and symptoms.”[] It probably needs to be redefined as “a science and art of identifying a disease from its signs and symptoms.” A myriad of information, in the form of history, clinical examination diagnostic aids are essential to reach a conclusion and formulate a plan of management. Here, risk assessment tools help in objectively organizing the data helpful in diagnosis, treatment, and research. Risk models estimate the risk of initial disease in apparently healthy, asymptomatic individuals based on the assessment of multiple variables. An ideal risk assessment tool is qualitative, simple to calculate (a pen and a piece of paper or a gadget), easy to interpret, and actionable. A woman is unique in her biological status and responds to endogenous and exogenous factors, as distinctly as one' fingerprint. At menopause transition, the differential response to the waxing and waning of hormones is based on their biological framework, microbiota, health status, presence of comorbidities, medications, mental makeup, socioeconomic, and cultural background. Hence, the challenge is to offer a holistic and personalized approach to manage menopause. Decision-making on each menopausal treatment has a unique benefit-risk profile affecting several clinical end points. An individual's menopausal symptoms and risks for breast cancer, cardiovascular disease, skeletomuscular health, genitourinary syndrome, and other prevalent diseases and their response to treatment are dynamic and change over time with age. Moreover, the benefit-risk profile of menopausal treatment for an individual depends on the patient's baseline disease risks, concurrent use of any drug that may interact with the treatment, and the impact of that treatment on quality of life. Therefore, weighing the risks and benefits of treatment individually can be complex. It is made simple, when based on the collective assessment derived from the risk assessment models. Established tools are available to screen for menopausal symptoms, cardiovascular disease, breast cancer, skeletomuscular health, and genitourinary syndrome in establishing the health status and guide in risk-benefit analysis for prescribing menopause therapy. The paper by Calman and Royston describes risks in colloquial language, which is easy to communicate and understand, and aid in making informed decisions.[] The risk assessment tools need to be a part of the armamentarium of a menopause practitioner. The Indian Menopause Society has described the tools for India, acknowledging the strengths and limitations.[] We thank Anna Fenton for a narrative review on weight, shape, and body composition changes at menopause, which will interest the readers and help in practice. In continuation of the endometrial hyperplasia series, Miland Telang and Tanvir present a pictorial review from their collection of hysteroscopic work. Each original article and the case reports are on topics of interest to the readers. We urge the readers to send their comments, and we would be happy to publish them. REFERENCES 1 Available from: https://www.merriam-webster.com/dictionary/ diagnosis. [2021Sep10].2 Calman KC, Royston G. Personal paper: Risk language and dialects. Br Med J. 1997;315:939-42.3 Meeta M, Digumarti L, Agarwal N, Vaze N, Shah R, Malik S. Clinical practice guidelines on menopause: *An executive summary and recommendations: Indian menopause society 2019-2020. J Midlife Health. 2020;11:55-9.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

References (3)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK